Former CDC Scientist Arrested in Germany Following $1 Million Grant Fraud Scheme
A former visiting scientist at the Centers for Disease Control and Prevention (CDC) is returning to the United States to face federal charges after allegedly orchestrating a sophisticated scheme to steal more than $1 million in research grants. Paul Thorsen, who worked within the CDC’s Division of Birth Defects and Developmental Disabilities, was arrested in Germany on June 4, 2025, following a decade-long legal pursuit.
Thorsen faces 22 counts of wire fraud and money laundering. The charges stem from a period between February 2004 and February 2010, during which he allegedly diverted funds intended for critical medical research into his personal bank accounts.
The Mechanics of the Fraud
According to the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), Thorsen exploited his position as a visiting scientist to manipulate the reimbursement process for international grants. The CDC had awarded funding to two Danish government entities: the Danish Medical Research Council and the Danish Agency for Science, Technology, and Innovation.
To divert the funds, Thorsen allegedly created fraudulent invoices using official CDC letterhead. He sent these invoices to medical facilities assisting in the research—specifically Aarhus University and Sahlgrenska University Hospital—requesting reimbursements for work purportedly covered by the grants. Because the invoices appeared to be official CDC requests, the institutions complied, but the funds were directed to a bank account owned personally by Thorsen rather than the research institutions.
Impact on Medical Research
The stolen funds were originally earmarked for vital studies concerning infant disabilities and developmental disorders. Assistant U.S. Attorney Steven McClain noted that the research scope included:
- The relationship between vaccines and autism.
- The prevalence of cerebral palsy in infants.
- The effects of fetal alcohol syndrome.
- Genetic disorders and developmental outcomes.
While the research was conducted by Aarhus University and Odense University Hospital in Denmark, the diversion of funds undermined the financial integrity of these federally funded projects.
Luxury Spending and Fugitive Status
Federal authorities allege that Thorsen used the diverted grant money to fund a lavish lifestyle. The stolen funds were reportedly used to purchase a home in Atlanta, an Audi, a Honda, and a Harley-Davidson motorcycle. Thorsen allegedly issued more than 60 cashier’s checks using the illicit proceeds.
Although Thorsen was indicted on 22 counts of wire fraud and money laundering in April 2011, he remained a fugitive until his recent apprehension in Germany. He is currently in the process of being extradited to the United States to stand trial.
Key Case Takeaways
| Detail | Case Fact |
|---|---|
| Defendant | Paul Thorsen |
| Total Alleged Theft | Over $1 million |
| Primary Charges | 22 counts of wire fraud and money laundering |
| Fraud Period | February 2004 – February 2010 |
| Arrest Date | June 4, 2025 |
Frequently Asked Questions
How did the scientist bypass CDC oversight?
Thorsen used fraudulent invoices printed on official CDC letterhead. This misled the collaborating hospitals in Denmark into believing the CDC was requesting the funds, while the payment instructions directed the money to Thorsen’s private account.
What happens next in the legal process?
Following his arrest in Germany, Thorsen is undergoing the extradition process to be returned to the U.S. Once back on American soil, he will face the 22 counts of fraud and money laundering filed against him in 2011.
Who is investigating this case?
The investigation was led by the HHS Office of Inspector General in coordination with federal prosecutors and international law enforcement agencies to secure the arrest in Germany.
This case serves as a stark reminder of the vulnerabilities in international grant management and the importance of rigorous auditing for federal research funding. As Thorsen returns to the U.S., the legal proceedings will likely shed further light on the gaps in oversight that allowed the scheme to persist for six years.